

Nivolumab CheckMate 017

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Less serious adverse events observed



Other adjustments



Nivolumab CheckMate 017

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies  
 Therapeutic Indication: Locally advanced or metastatic squamous NSCLC after prior ChT  
 Experimental Arm: Nivolumab  
 Control Arm: Docetaxel

